1 |
Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
DOI
ScienceOn
|
2 |
Baylin SB, Jones PA. A decade of exploring the cancer epigenome: biological and translational implications. Nat Rev Cancer 2011;11:726-734.
DOI
ScienceOn
|
3 |
Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
DOI
ScienceOn
|
4 |
Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007;148:948-953.
DOI
|
5 |
Hu S, Liu D, Tufano RP, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006;119:2322-2329.
DOI
ScienceOn
|
6 |
Porra V, Ferraro-Peyret C, Durand C, et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 2005;90:3028-3035.
DOI
ScienceOn
|
7 |
Schneider-Stock R, Roessner A, Ullrich O. DAP-kinase: protector or enemy in apoptotic cell death. Int J Biochem Cell Biol 2005;37:1763-1767.
DOI
ScienceOn
|
8 |
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-793.
DOI
ScienceOn
|
9 |
Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005;5:376-387.
DOI
ScienceOn
|
10 |
Kim TY, Lee HJ, Hwang KS, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 2004;84:479-484.
DOI
ScienceOn
|
11 |
Ko HJ, Kim BY, Jung CH, et al. DNA methylation of RUNX3 in papillary thyroid cancer. Korean J Intern Med 2012;27:407-410.
DOI
ScienceOn
|